Clinical Advances in Cervical Cancer: Extending Survival With Novel Targeted Therapy - A Case Study Challenge
Hematology-Oncology
Curriculum:
Clinical Advances in Cervical Cancer: Extending Survival With Novel Targeted Therapy
Clinical Advances in Cervical Cancer: Extending Survival With Novel Targeted Therapy
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
October 31, 2014
October 31, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Medical oncologists, gynecological oncologists, gynecologists, pathologists, and other healthcare professionals who manage patients with cervical cancer
Relevant Terms:
Gynecological Oncology
Krishnansu S. Tewari, MD, FACOG, FACS
Krishnansu S. Tewari, MD, FACOG, FACS
Professor and Director of Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California Irvine Medical Center
Orange, California
Bio
Dr. Krishnansu S. Tewari is Professor and Director of Research in the Division of Gynecologic Oncology at the University of California Irvine Medical Center in Orange. He received his Bachelor of Science degree in Molecular Biology at the University of California, Berkeley. Dr. Tewari then completed medical school, a fellowship in gynecologic oncology, and a residency in obstetrics and gynecology at the University of California, Irvine. He currently serves as principal investigator of the National Cancer Institute’s NRG-Oncology Cooperative Group and Gynecologic Oncology Group Partners at the University of California, Irvine. Dr. Tewari is also a voting member of the NRG’s Cervix Committee, Publications Committee, and Committee on Experimental Medicine. He is also the Chairman of the Protocol Review and Monitoring Committee and the Director of the Gynecologic Cancer Disease Oriented Team for the Chao Family National Cancer Institute Designated Comprehensive Cancer Center. Additionally, Dr. Tewari is the Director of the Gynecologic Oncology Program at St Joseph's Center for Cancer Prevention and Treatment in Orange, California and Chairman of the Society of Gynecologic Oncology Publications Committee.
Dr. Tewari has published over 100 peer reviewed articles and written numerous book chapters. His research interests include novel targeted therapeutics in ovarian cancer and cervical cancer. Dr. Tewari is funded by the National Institutes of Health to study surrogate markers of angiogenesis in cervical cancer and is the Study Chair/Principal Investigator for Gynecologic Oncology Group protocol 240, the practice-changing phase 3 randomized clinical trial which demonstrated that compared to chemotherapy alone, the addition of the anti-angiogenesis drug, bevacizumab, significantly improved overall survival, progression-free survival, and response rate without a significant deterioration in health-related quality of life. This pivotal trial led to approval by the U.S. Food and Drug Administration on August 14, 2014, of bevacizumab in advanced cervical cancer. Dr. Tewari has been listed for seven consecutive years as one of the Top Doctors in Orange County and has been listed in Best Doctors of America for the past 4 years. An expert in robotic surgery, for the past 2 years Dr. Tewari has been travelling every eight months to conduct robotic surgery workshops in different cities of India for women diagnosed with early stage cervical and endometrial cancer.
Robert A. Burger, MD, FACOG, FACS
Robert A. Burger, MD, FACOG, FACS
Professor of Obstetrics and Gynecology
Director of Clinical Research
Fellowship Program Director
University of Pennsylvania
Philadelphia, Pennsylvania
Bio
Dr. Robert A. Burger is Professor of Obstetrics and Gynecology, Director of Clinical Research, and Fellowship Program Director at the University of Pennsylvania in Philadelphia. He specializes in the care of women with gynecologic cancers. Dr. Burger is a member of the National Cancer Institute Gynecologic Cancer Steering Committee Ovarian Task Force. He is also a fellow of the American College of Surgeons and the American College of Obstetricians and Gynecologists.
Dr. Burger received his doctor of medicine degree from New York University School of Medicine in New York City. He completed a residency in obstetrics and gynecology at the University of Pennsylvania and a fellowship in gynecologic oncology at the University of California, Irvine.
Dr. Burger received his doctor of medicine degree from New York University School of Medicine in New York City. He completed a residency in obstetrics and gynecology at the University of Pennsylvania and a fellowship in gynecologic oncology at the University of California, Irvine.
| 1. | Counsel patients on the importance of HPV vaccination | 2. | Utilize risk factors and screening guidelines for prevention and early detection of cervical cancer |
| 3. | Assess the role of current treatment strategies for cervical cancer patients, including surgery, radiation therapy, and chemotherapy approaches | 4. | Discuss the role of anti-VEGF therapy in cervical cancer |
| 5. | Evaluate updated results for emerging treatment strategies for patients with cervical cancer to develop treatment strategies that optimally integrate targeted therapy into treatment paradigms |
| 1. | Counsel patients on the importance of HPV vaccination |
| 2. | Utilize risk factors and screening guidelines for prevention and early detection of cervical cancer |
| 3. | Assess the role of current treatment strategies for cervical cancer patients, including surgery, radiation therapy, and chemotherapy approaches |
| 4. | Discuss the role of anti-VEGF therapy in cervical cancer |
| 5. | Evaluate updated results for emerging treatment strategies for patients with cervical cancer to develop treatment strategies that optimally integrate targeted therapy into treatment paradigms |
Estimated Time to Complete Activity: 1 hour
Target Audience
This activity is intended for medical oncologists, gynecological oncologists, gynecologists, pathologists, and other healthcare professionals who diagnose, treat, and manage cervical cancer.
Purpose
The goal of this activity is to provide clinicians with the most recent clinical advances in cervical cancer and the application of current evidence to clinical practice to improve patient outcomes and quality of life.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
To contact PIM, please visit www.pimed.com.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Robert A. Burger, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: consulting fee, Amgen, Inc., Boehringer Ingelheim, Genentech, Inc.
Krishnansu S. Tewari, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: advisory board, Caris Life Sciences, Inc., ADVAXIS, and Genentech, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS; Diedrea White, BA; and Deborah Middleton, MS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness
There is no fee for this educational activity.
Jointly provided by
This activity is supported by an independent educational grant from Genentech.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. |
